KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Cost of Revenue Over TimeStable
Percentile Rank77
5Y CAGR-15.6%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
-15.6%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$17.71M-
2025$0.00-100.0%
2024$86.17M-
2023$0.00-
2022$0.00-100.0%
2021$41.29M+2.7%
2020$40.19M+114671.1%
2019$35021.00+92.0%
2018$18237.00+44.0%
2017$12666.00-